PT  - JOURNAL ARTICLE
AU  - GORNET, MATTHEW F.
AU  - LANMAN, TODD H.
AU  - BURKUS, J. KENNETH
AU  - HODGES, SCOTT D.
AU  - MCCONNELL, JEFFREY R.
AU  - DRYER, RANDALL F.
AU  - SCHRANCK, FRANCINE W.
AU  - COPAY, ANNE G.
TI  - One-Level Versus 2-Level Treatment With Cervical Disc Arthroplasty or Fusion: Outcomes Up to 7 Years
AID  - 10.14444/6076
DP  - 2019 Dec 01
TA  - International Journal of Spine Surgery
PG  - 551--560
VI  - 13
IP  - 6
4099  - https://www.ijssurgery.com/content/13/6/551.short
4100  - https://www.ijssurgery.com/content/13/6/551.full
SO  - Int J Spine Surg2019 Dec 01; 13
AB  - Background: Anterior cervical discectomy and fusion (ACDF) and cervical disc arthroplasty (CDA) have been used to treat degenerative disc disease at single as well as multiple cervical levels. This study compares the safety and efficacy of 1-level versus 2-level CDA and ACDF.Methods: In total, 545 and 397 patients with degenerative disc disease were studied in 1-level and 2-level Food and Drug Administration (FDA)–approved clinical trials, respectively: CDA (n = 280 and 209), ACDF (n = 265 and 188). Data from these studies were used to compare 1- versus 2-level procedures: the propensity score method was used to adjust for potential confounding effects, and adjusted mean outcome safety and efficacy scores at 2 and 7 years postsurgery were compared between 1-level and 2-level procedures within treatment type.Results: One-level and 2-level procedures had similar rates of improvement in overall success and patient-reported outcomes scores for both CDA and ACDF. There were no statistical differences in rates of implant-related adverse events (AEs) or serious implant-related AEs between 1-level and 2-level CDA. The 7-year rate of implant-related AEs was higher for 2-level than 1-level ACDF (27.7% vs 18.9%, P ≤ .036), though the rates of serious implant-related AEs between ACDF groups did not differ significantly. Secondary surgery rates were not statistically different between 1-level and 2-level procedures (CDA or ACDF) at the index or adjacent levels at 2 or 7 years. Grade IV heterotopic ossification at 7 years was reported in 4.6% of 1-level CDA patients and 8.6%/7.3% at the superior/inferior levels, respectively, of 2-level CDA patients.Conclusions: One- and 2-level CDA appear equally safe and effective in the treatment of cervical degenerative disc disease. Two-level ACDF appears to be as effective as 1-level ACDF but with a higher rate of some AEs at long-term follow-up.Level of Evidence: 2.Clinical Trials: clinicaltrials.gov: NCT00667459, NCT00642876, and NCT00637156.